Combining anti-tumor necrosis factor therapy with cIAP1/2 inhibitors by blocking the BIRC2/BIRC3-mediated apoptotic pathway has the potential to improve therapeutic efficacy and effectively reduce symptoms and disease progression in rheumatoid arthritis. Here, BIRC2 is linked to rheumatoid arthritis.